Pricing Log in Create free account
Friday 6 November 2026 Export CYTK’s income statement to Excel — free account

Cytokinetics, Incorporated

CYTK Healthcare Biotechnology

Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.

Revenue
+2,356.5%
EPS
+46.3%
Free cash flow
−6.73%
Total debt
−83.9%

Quarter to September 2026, against a year earlier

53.84 1.71 −3.08%
Market cap
$7.7B
P/E
0.0×
Fwd P/E
−10.3×
Dividend yield
—
F-score
2/9
Altman Z
−1.98
Beneish M
−0.44
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Cytokinetics, Incorporated 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:30 PM ET · Document on sec.gov · Filing index

Red flags

  • Short cash runway

    Cytokinetics, Incorporated’s cash and short-term investments cover about 1.4 quarters of its operating cash burn

    10-Q filed · The filing · sec.gov

  • Share dilution

    Shares outstanding rose 13.9% in a year, to 139.3 million

    10-Q filed · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Aug 6, 2026: no comparison — the earlier filing's Item cannot be compared